Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IceCure Medical (ICCM) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for IceCure Medical (ICCM) over the last 6 years, with Q3 2025 value amounting to 454.0%.

  • IceCure Medical's EBITDA Margin fell 1727400.0% to 454.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 513.95%, marking a year-over-year increase of 1371000.0%. This contributed to the annual value of 465.45% for FY2024, which is 116900.0% up from last year.
  • According to the latest figures from Q3 2025, IceCure Medical's EBITDA Margin is 454.0%, which was down 1727400.0% from 640.76% recorded in Q2 2025.
  • In the past 5 years, IceCure Medical's EBITDA Margin registered a high of 1223.24% during Q3 2023, and its lowest value of 95.47% during Q1 2021.
  • In the last 5 years, IceCure Medical's EBITDA Margin had a median value of 485.73% in 2024 and averaged 490.01%.
  • As far as peak fluctuations go, IceCure Medical's EBITDA Margin surged by 7128700bps in 2021, and later tumbled by -5965000bps in 2024.
  • Quarter analysis of 5 years shows IceCure Medical's EBITDA Margin stood at 228.32% in 2021, then surged by 84bps to 420.87% in 2022, then plummeted by -43bps to 238.65% in 2023, then surged by 114bps to 511.89% in 2024, then dropped by -11bps to 454.0% in 2025.
  • Its EBITDA Margin stands at 454.0% for Q3 2025, versus 640.76% for Q2 2025 and 494.9% for Q1 2025.